Platin Analoglarının Etki Mekanizmaları ve Sınıflandırılması
Özet
Platin bazlı kemoterapötik ajanlar, modern kanser tedavisinin temel taşlarından birini oluşturmakta ve sisplatin, karboplatin ile oksaliplatin gibi önde gelen analoglar aracılığıyla özellikle solid tümörlere karşı yaygın olarak kullanılmaktadır. Bu bileşikler, hücre içine bakır transporter 1 (CTR1) gibi taşıyıcı mekanizmalarla girdikten sonra aktif formlarına dönüşerek hücresel proteinlere ve öncelikli olarak nükleer DNA'ya bağlanır; guanin bazlarında oluşturdukları çapraz bağlar sayesinde DNA sentezini inhibe ederek hücreyi apoptozise sürükler. Ancak, ilaçların tümör dokusunun yanında hızlı bölünen sağlıklı hücreleri de etkilemesi; nefrotoksisite, nöropati, gastrointestinal ve kemik iliği toksisitesi gibi ciddi doz kısıtlayıcı yan etkilere yol açmaktadır. Bunun yanı sıra, hücresel alımın azalması, glutatyon gibi moleküllerle deaktivasyon ve NER gibi DNA tamir mekanizmalarının aktivasyonu yoluyla gelişen pre-target, on-target, post-target ve off-target direnç mekanizmaları tedavinin başarısını sınırlayan en büyük engellerdir. İkinci ve üçüncü nesil platin analogları bu toksisite ile direnç sorunlarını aşmak amacıyla geliştirilmiş olup, günümüzde hedefe yönelik yeni kombinasyonlar ve biyobelirteç çalışmalarıyla platin bazlı tedavilerin klinik potansiyeli optimize edilmeye çalışılmaktadır.
Platinum-based chemotherapeutic agents constitute one of the cornerstones of modern cancer treatment and are widely utilized against solid tumors, primarily through leading analogs such as cisplatin, carboplatin, and oxaliplatin. Upon entering the cell via transport mechanisms like copper transporter 1 (CTR1), these compounds transform into highly reactive forms and bind to cellular proteins and nuclear DNA; by forming cross-links particularly at guanine residues, they inhibit DNA synthesis and drive the cell toward apoptosis. However, because these cytotoxic drugs affect rapidly dividing healthy cells alongside tumor tissues, they induce severe dose-limiting side effects including nephrotoxicity, neuropathy, gastrointestinal distress, and bone marrow toxicity. Furthermore, drug resistance, which develops through pre-target, on-target, post-target, and off-target mechanisms—such as decreased cellular uptake, drug deactivation by glutathione, and enhanced DNA repair via NER pathways—poses a major challenge to treatment efficacy. Second- and third-generation platinum analogs were specifically engineered to overcome these toxicity and resistance barriers, and current oncological research continues to optimize their clinical potential through novel targeted combinations and predictive biomarkers.
Referanslar
M. G. Apps, E. H. Y. Choi and N. J. Wheate, Endocr.-Relat. Cancer, 2015, 22, R219–R233.
G. Ferraro, L. Massai, L. Messori and A. Merlino, Chem. Commun., 2015, 51, 9436–9439.
G. V. Kalayda, C. H. Wagner and U. Jaehde, J. Inorg. Biochem., 2012, 116, 1–10.
Z. D. Liang, Y. Long, H. H. W. Chen, N. Savaraj and M. T. Kuo, J. Biol. Inorg. Chem., 2014, 19, 17–27.
T. C. Johnstone, K. Suntharalingam and S. J. Lippard, Chem. Rev., 2016, 116, 3436–3486.
L. Amable, Pharmacol. Res., 2016, 106, 27–36.
Oun, R., Moussa, Y. E., & Wheate, N. J. (2018). The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton transactions, 47(19), 6645-6653.
Wiltshaw E (1979) Cisplatin in the treatment of cancer. Platin Met Rev 23:90–98
Galanski M (2006) Recent developments in the field of anticancer platinum complexes. Recent Pat Anticancer Drug Discov 1:285–295
Lebwohl D, Canetta R (1998) Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 34:1522–1534
Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G (2012) Molecular mechanisms of cisplatin resistance. Oncogene 31:1869–1883
Kalayda GV, Wagner CH, Jaehde U (2012) Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells. J Inorg Biochem 116:1–10
Safaei R (2006) Role of copper transporters in the uptake and efflux of platinum containing drugs. Cancer Lett 234:34–39
Holzer AK, Manorek GH, Howell SB (2006) Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol 70:1390–1394
Zisowsky J, Koegel S, Leyers S, Devarakonda K, Kassack MU, Osmak M, Jaehde U (2007) Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells. Biochem Pharmacol 73:298–307
Yang T, Chen M, Chen T, Thakur A (2015) Expression of the copper transporters hCtr1, ATP7A and ATP7B is associated with the response to chemotherapy and survival time in patients with resected non-small cell lung cancer. Oncol Lett 10:2584–2590
Kalayda GV, Wagner CH, Buss I, Reedijk J, Jaehde U (2008) Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells. BMC Cancer 8:175
Samimi G, Safaei R, Katano K, Holzer AK, Rochdi M, Tomioka M, Goodman M, Howell SB (2004) Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin Cancer Res 10:4661–4669
Planells-Cases R, Lutter D, Guyader C, Gerhards NM, Ullrich F, Elger DA, Kucukosmanoglu A, Xu G, Voss FK, Reincke SM, Stauber T, Blomen VA, Vis DJ, Wessels LF, Brummelkamp TR, Borst P, Rottenberg S, Jentsch TJ (2015) Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugs. EMBO J 34:2993–3008
Borst P, Evers R, Kool M, Wijnholds J (2000) A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295–1302
Yamasaki M, Makino T, Masuzawa T, Kurokawa Y, Miyata H, Takiguchi S, Nakajima K, Fujiwara Y, Matsuura N, Mori M, Doki Y (2011) Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma. Br J Cancer 104:707–713
Takahara PM, Rosenzweig AC, Frederick CA, Lippard SJ (1995) Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Nature 377:649–652
Brown SJ, Kellett PJ, Lippard SJ (1993) Ixr1, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin. Science 261:603–605
Huang JC, Zamble DB, Reardon JT, Lippard SJ, Sancar A (1994) HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc Natl Acad Sci USA 91:10394–10398
Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, Pommier Y (2002) Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 62:4899–4902
Vaisman A, Varchenko M, Umar A, Kunkel TA, Risinger JI, Barrett JC, Hamilton TC, Chaney SG (1998) The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 58:3579–3585
Kirsch DG, Kastan MB (1998) Tumor-suppressor p53: implications for tumor development and prognosis. J Clin Oncol 16:3158–3168
Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ (2008) Medical treatment of advanced testicular cancer. JAMA 299:672–684
Peng HQ, Hogg D, Malkin D, Bailey D, Gallie BL, Bulbul M, Jewett M, Buchanan J, Goss PE (1993) Mutations of the p53 gene do not occur in testis cancer. Cancer Res 53:3574–3578
Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Raju S, Wiltshaw E, Smith IE, Baker JM, Peckham MJ, Harrap KR (1982) Early clinical studies with cisdiammine-1, 1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 9:140–147
Stewart DJ (2007) Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 63:12–31
Wheate NJ, Walker S, Craig GE, Oun R (2010) The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans 39:8113–8127
Zhang S, Lovejoy KS, Shima JE, Lagpacan LL, Shu Y, Lapuk A, Chen Y, Komori T, Gray JW, Chen X, Lippard SJ, Giacomini KM (2006) Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res 66:8847–8857
Tashiro A, Tatsumi S, Takeda R, Naka A, Matsuoka H, Hashimoto Y, Hatta K, Maeda K, Kamoshida S (2014) High expression of organic anion transporter 2 and organic cation transporter 2 is an independent predictor of good outcomes in patients with metastatic colorectal cancer treated with FOLFOX- based chemotherapy. Am J Cancer Res 4:528–536
Martinez-Balibrea E, Martínez-Cardús A, Ginés A, Ruiz de Porras V, Moutinho C, Layos L, Manzano JL, Bugés C, Bystrup S, Esteller M, Abad A (2015) Tumor-related molecular mechanisms of oxaliplatin resistance. Mol Cancer Ther 14:1767–1776
Di Francesco AM, Ruggiero A, Riccardi R (2002) Cellular and molecular aspects of drugs of the future: oxaliplatin. Cell Mol Life Sci 59:1914–1927
Dilruba, S., & Kalayda, G. V. (2016). Platinum-based drugs: past, present and future. Cancer chemotherapy and pharmacology, 77(6), 1103-1124.
